Showing results (291-300 of 391) with videos related to
Sort By:
Pageof 40
The Journal of Pathology|November 18, 2017
MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion geneJisun Kim, Felipe C Geyer, Luciano G Martelotto, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 19, 2024
Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer ConsortiumMaxim De Schepper, Thijs Koorman, François Richard, et al.Nature Communications|October 14, 2024
Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafuspManuel Rodrigues, Toulsie Ramtohul, Aurore Rampanou, et al.European Journal of Cancer (Oxford, England : 1990)|March 26, 2022
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancerSuzette Delaloge, Sylvain Dureau, Véronique D'Hondt, et al.Oncogene|November 4, 2022
Microsatellite instability detection in breast cancer using drop-off droplet digital PCRKhadidja Zeyneb Klouch, Marc-Henri Stern, Olfa Trabelsi-Grati, et al.Genes & Development|December 6, 2015
Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesisMichel Wassef, Veronica Rodilla, Aurélie Teissandier, et al.Nature Communications|December 10, 2025
A recurrent pathogenic BRCA2 truncating variant reveals a role for BRCA2-PCAF complex in modulating NF-κB-driven transcriptionAnna Minello, Jesus Gomez-Escudero, Sreerama Chaitanya Sridhara, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2018
Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 TrialAlice Bernard-Tessier, Emmanuelle Jeannot, David Guenat, et al.Theranostics|February 12, 2020
Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenograftsFlorence Coussy, Marion Lavigne, Leanne de Koning, et al.Nature Communications|May 12, 2026
E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancerLounes Djerroudi, Rana Mhaidly, Yann Kieffer, et al.Pageof 40